Mastercard and Riskified New Integration Combines Fraud Insights to Drive Ecommerce Revenue Growth and Profitability for Global Merchants
17.8.2023 15:30:00 EEST | Business Wire | Press release
Riskified (NYSE:RSKD), a leader in ecommerce fraud and risk intelligence, today announced an enhanced partnership with global payments leader Mastercard, that will improve the ability of businesses across the globe to grow online revenues and profit while mitigating the risk of fraud and chargebacks.
Riskified’s machine learning platform provides merchant fraud teams with highly accurate, automated risk-decisioning for ecommerce transactions. This partnership breaks new ground in the ecommerce fraud space by marrying insights from Mastercard’s world-leading cybersecurity products and solutions with Riskified’s extensive transaction and identity network. The partnership also provides access to Mastercard’s suite of tools that enable real-time alerts on chargeback events and facilitate automated dispute resolution.
“This global partnership with Mastercard highlights the measurable impact Riskified makes on merchant revenues and profitability,” said Kevin Sprake, Vice President, Global Channel Partnerships at Riskified. “We're excited to work with Mastercard to empower merchants to continue investing in ecommerce to drive growth across the globe, and particularly in emerging markets where merchants have higher exposures to fraud and abuse.”
For more information on Riskified Partners, visit riskified.com/partners.
About Riskified
Riskified (NYSE:RSKD) empowers businesses to grow ecommerce revenues and profit by mitigating risk. An unrivaled network of merchant brands including Wayfair, Booking.com, and Prada partner with Riskified for guaranteed protection against chargebacks, to fight fraud and policy abuse at scale, and to improve customer retention. Developed and managed by the largest team of ecommerce risk analysts, data scientists and researchers, Riskified’s AI-powered fraud and risk intelligence platform analyzes the individual behind each interaction to provide real-time decisions and robust identity-based insights. Learn more at Riskified.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817028316/en/
Contact information
Aileen McNelis
PR for Riskified
amcnelis@nexttechcomms.com
Cristina Dinozo
Sr. Director of Communications
press@riskified.com
Chett Mandel
Head of Investor Relations
ir@riskified.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vecima, Incognito, and BM COM Announce Turnkey Fiber Broadband Solutions at ANGA COM 202613.5.2026 14:30:00 EEST | Press release
Vecima Networks Inc., Incognito Software Systems Inc., and BM COM s.r.o., today announced a strategic collaboration to deliver a fully integrated, turnkey fiber broadband solution, which will be showcased at ANGA COM 2026, May 19–21 in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513492655/en/ The joint solution brings together best-in-class fiber access infrastructure, advanced service orchestration, and in-market deployment expertise into a unified, interoperable Broadband-in-a-Box platform without requiring single vendor lock-in. Designed to simplify and accelerate fiber broadband rollouts, the solution enables operators—particularly regional and emerging providers—to deploy scalable, high-performance networks with reduced complexity and faster time to revenue. The joint Vecima, Incognito, and BM COM Broadband-in-a-Box solution integrates: Vecima’s Entra® XGS-PON platform, delivering scalable, high-
Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days * Without Regulatory Risks13.5.2026 14:05:00 EEST | Press release
Veristat™, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStat™ by Veristat. InStat is the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks sponsors typically wait after database lock, while maintaining the highest quality data. Veristat will begin using InStat to deliver biostatistics services in June. Clene Nanomedicine is the first clinical trial sponsor whose work was delivered using InStat, with NfL biomarker analyses supporting their planned 2026 New Drug Application (NDA). "Following recent FDA interactions, we are advancing our NDA submission for CNM-Au8 with NfL biomarker concordance evidence as a core compon
Carta Launches Carta Law with Acquisition of Avantia13.5.2026 14:01:00 EEST | Press release
Carta, the agentic enterprise resource planning (ERP) platform for private capital, today announced it has acquired Avantia, a leading AI-powered legal and compliance law firm for asset managers. The acquisition launches Carta Law—the largest AI-native, integrated legal and compliance solution for private markets—unifying legal and compliance workflows with fund operations on a single platform. Private capital firms have long operated with fragmented infrastructure, with fund administration, compliance, and legal services spread across separate vendors. Deal teams wait days for NDAs. Limited partner onboarding to new funds is delayed by KYC backlogs. General counsels lose visibility into legal spend or institutional precedent. As deal velocity increases and regulatory complexity grows, this fragmentation becomes a competitive disadvantage and operational barrier for funds. With the acquisition of Avantia and the introduction of Carta Law, the industry will have a single-platform soluti
Amazfit Unveils the Cheetah 2 Ultra: The Performance Trail Running Watch Built to Master the Toughest Mountain Trails13.5.2026 14:00:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Cheetah 2 Ultra. Building on the momentum of the recently launched Cheetah 2 Pro—designed for road marathoners—the Ultra is a specialized instrument for trail runners who measure success in elevation, unpredictable terrain, and hours spent on the move. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513230718/en/ Built for ultra distances and mountain racing, the Cheetah 2 Ultra combines long battery life, precision navigation, and advanced training insights to carry more distance and control more load. Amazfit’s Cheetah 2 Ultra is built for runners who prepare for ultra distances and mountain races, boasting 33-hour trail running optimized GPS battery life, full-color contour maps, Grade 5 titanium construction, and advanced training and recovery insights. Amazfit designed the Cheetah 2 Ultra to support the preparation required for lo
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights13.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights. “With regulatory acceleration unfolding, we are working diligently towards our goal of completing the filing of a robust clinical package by Q4 and securing COMP360 approval,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “COMP360 represents a fundamentally different approach for patients with treatment resistant depression, unlike any other treatment approved today. Its transformative clinical profile has the potential to change what patients can expect in terms of both rapid and durable relief, and we are ready to deliver for those who have waited far too long for better options.” Business Highlights Accelerated regulatory path Approval timelines are tracking to Compass’ fastest projected expectations, supported by regulatory acceleration includi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom